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Thyroid hormones regulate brain development and function through the control of gene
expression, mediated by binding of T3 to nuclear receptors. Brain T3 concentration is tightly
controlled by homeostatic mechanisms regulating transport and metabolism of T4 and T3. We
have examined the role of the inactivating enzyme type 3 deiodinase (D3) in the regulation of
43 thyroid hormone-dependent genes in the cerebral cortex of 30-d-old mice. D3 inactivation
increased slightly the expression of two of 22 positively regulated genes and significantly
decreased the expression of seven of 21 negatively regulated genes. Administration of high
doses of T3 led to significant changes in the expression of 12 positive genes and three negative
genes inwild-typemice. The response to T3 treatmentwas enhanced in D3-deficientmice, both
in the number of genes and in the amplitude of the response, demonstrating the role of D3 in
modulating T3 action. Comparison of the effects on gene expression observed in D3 deficiency
with those in hypothyroidism, hyperthyroidism, and type 2 deiodinase (D2) deficiency revealed
that the negative genes are more sensitive to D2 and D3 deficiencies than the positive genes.
This observation indicates that, in normal physiological conditions, D2 and D3 play critical roles
in maintaining local T3 concentrations within a very narrow range. It also suggests that neg-
atively and positively regulated genes do not have the same physiological significance or that
their regulation by thyroid hormone obeys different paradigms at the molecular or cellular
levels. (Endocrinology 153: 0000–0000, 2012)
Thyroidhormones are important for braindevelopmentand function (1–3). Most of their effects in the brain
and other tissues are mediated by regulating gene expres-
sion at the transcriptional and post transcriptional levels
(4). Thyroid hormone regulation of gene expression in the
brain is extremely complex and depends on age and the
particular brain regionand cell type (5).The active thyroid
hormone isT3,whichbinds to specific nuclear receptors to
either repress or activate gene transcription (6). T3 is
formed in the thyroid gland but also in peripheral tissues
from the precursor T4 by the action of the 5-deiodinase
type 1 and 5-deiodinase type 2 (D2) (7). In the brain and
other tissues, such as brown adipose tissue and pituitary,
local generationofT3byD2 is an important step in thyroid
hormone-dependent biological effects (8–11). D2 is en-
coded by theDio2 gene, and its activity is regulated by T4
through a nongenomic effect on protein degradation (12).
This posttranslational effect is the main control of D2
activity and does not imply changes in the mRNA con-
centration. However, pretranslational effects involving
changes in the concentration ofDio2mRNAalso occur in
response to hypothyroidism and T3 treatment (13). The
Dio2 gene is expressed in astrocytes and in the specialized
glial cells called tanycytes lining the inferior walls of the
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third ventricle (14, 15). Cellular targets of T3 also include
neurons and oligodendrocytes, which express T3 recep-
tors and, in normal physiological conditions, lack D2 ac-
tivity (16).
The T3 reaching the target cells in the central nervous
system has two origins. One is the circulation, fromwhich
T4 and T3 cross the blood-brain barrier (BBB) through
specific transporters (17). In the astrocytes, T3 is also gen-
erated from T4 by the action of D2. It is thought that the
Slco1c1 transporter (18), expressed in the membrane of
endothelial capillary cells, facilitates the passage of T4
through the BBB (19). Slco1c1 is also expressed in the
astrocytic end feet, which are in close contact with the
surface of the capillary endothelium (19). Therefore, it is
likely that T4 entering the brain from the circulation
through this route finds its way directly to the astrocytes,
in which T3 is formed. Thus, it is presumed that no sig-
nificant diffusion of T4 to the interstitial fluid does occur.
On the other hand, T4 and T3 also cross the BBB through
a very important transporter, the monocarboxylate 8
(Mct8, Slc16a2) transporter (20). Mct8 is specific for T4
and T3 and is not present in the astrocytic end feet (19).
Therefore, it is likely that T4 and T3 crossing the BBB
through Mct8 are delivered to the interstitial fluid from
which they can reach the target cells (21).
Another determinant of brain thyroid hormone action
is type 3 deiodinase (D3), which is encoded by the im-
printed gene Dio3 (7, 22). D3 catalyzes the formation of
the inactive metabolites rT3 from T4 and T2 from T3 (7,
22). It is believed that D3 has an important role in limiting
the amount of T3 reaching target tissues and preventing
excessive exposure to the hormone (9). According to this
view, the high D3 activities present in the uterus during
implantation and in the placenta (23) would limit the
amounts of thyroid hormone reaching the conceptus. In
thebrainDio3 is expressed inneurons (24, 25), andduring
perinatal development, neuronalD3would tightly control
the amount of T3 accumulating in the brain. We have
recently proposed that one role of D3 could be to restrict
the availability of T3 from the circulation so that most T3
acting in the brain during the fetal, and perhaps early post-
natal periods, would be derived from T4 in the astrocytes
(21). Consistent with the proposed role of D3, Dio3
knockout (KO)mouse neonatesmanifest elevated T3 con-
centration in the brain and increased expression of the T3
target genes Hr and Nrgn (26).
Previous findings using amousemodel ofD2deficiency
suggest that T3-regulated genes expressed in the cerebral
cortex exhibit different sensitivity in their response to T3,
depending on whether they are positively or negatively
regulated genes (27). In the present studies, we have an-
alyzed the expression of a large set of those genes in re-
sponse to hyperthyroidism andD3 deficiency. Our results
further support the notion of differential T3 sensitivity
between those groups of genes and reveal an unsuspected
complexity in the mechanisms by which thyroid hormone
metabolism at the local level finely regulates gene expres-
sion in the central nervous system.
Materials and Methods
In vivo studies
Protocols for animal handling were approved by the local
institutional Animal Care Committee, following the rules of
the European Union and the National Institutes of Health.
Animals were housed in temperature- (22  2 C) and light
(12-h light, 12-h dark cycle; lights on at 0700 h)-controlled
conditions and had free access to food and water. Chemical
hypothyroidism was induced in wild-type (WT) mice of the
C57/BL/6J strain by administering 0.02% 1-methyl-2-mer-
capto-imidazol (Sigma Chemical Co., St. Louis, MO) plus 1%
KClO4 in the drinking water ad libitum. These antithyroid
drugs were given to pregnant and lactating dams from gesta-
tional d 17, until postnatal (P) d 21. Dio3KO mice were in a
mixed C57/BL/6J and 129/Sv background as described (26). Ex-
periments involving comparisons between WT and Dio3KO
mice, as well as T3 treatments, were performed using WT and
Dio3KO littermates obtained from heterozygous parents. Hy-
perthyroidismwas induced by administration of 0.5g/ml of T3
and 0.1 g/ml of T4 in the drinking water containing 0.1% BSA
from P21 to P30. The corresponding doses were 1.0 g T3 and
0.2 g T4 per mice per day. Although T3 was in excess, the T4
dose was physiological. The rationale of this treatment was to
maintain physiological circulating concentrations of T4, as the
D2 substrate, in the face of T3-induced hyperthyroidism. Han-
dling of the Dio2KO mice was as previously described (27).
The pups were killed by decapitation on P21, to analyze the
effects of hypothyroidism and Dio2 deletion, or on P30 to an-
alyze the effects of hyperthyroidism andDio3 inactivation. The
whole neocortex was rapidly dissected out from underlying
structures, cut in twohalves through the sagittal plane, frozen on
dry ice, and kept at 80 C. RNA was isolated from individual
hemicortices. Procedures for RNA isolation and quantitative
PCR (qPCR) on TaqMan arrays (Applied Biosystems, Foster
City, CA), were as previously described (27). Data were ex-
pressed relative to the values obtained for the controlWT,which
was given a value of 1.0 after correction for 18S RNA and Ppia
mRNA. Thyroid hormone concentration in serum was deter-
mined as previously described (26).
Cell culture and transfection
Mouse neuroblastoma (N2a CA3 clone) cell lines expressing
the thyroid hormone receptor-1 isoform (TR1) were cultured
as described (28). The cells were seeded in each of six-well
plates with DMEM containing 10% thyroid hormone-de-
prived fetal calf serum (29) up to 80% confluence. The cells
were transfected with 0.5 g of a Dio3-expression clone in
pcDNA (Invitrogen, Carlsbad, CA) using Lipofectamine 2000
as described by the manufacturer (Invitrogen). Control cells
were transfected with empty pcDNA plasmid. Transfection
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efficiency was 18%. Twenty-four hours after transfection, T3
was added at final concentrations of 0.1 and 0.5 nM in trip-
licate, and the cells were incubated for a further 24 h before
harvesting and RNA isolation. The response to T3 was ana-
lyzed by qPCR using as target the Hr gene.
D2 and D3 activities
D2 and D3 enzymatic activities were determined as previ-
ously described (30, 31). In brief, tissues were homogenized in a
10 mM Tris-HCl, 0.25 sucrose (pH 7.4) buffer. A suitable
amount of tissue homogenatewas used in the enzymatic reaction
to ensure that deiodination did not exceed 20% and was pro-
portional to the amount of protein content. Tissue homogenates
were incubated at 37 C for an hour with the appropriate [125I]-
labeled substrate (PerkinElmer, Waltham, MA) in the presence
of 25 nM dithiothreitol. For D2 and D3 activity, homogenates
were incubated, respectively, with 1 nM T4 or 2 nM T3. Deiodi-
nationwas determined based on the percentage of labeled iodine
released (D2)or the amountof labeled3,3-diiodothyroninepro-
duced. The latter was determined after separation of reaction
products by paper chromatography, as described (32). A factor
of 2 was included in the calculation of D2 activity to correct for
the chemical equivalence of the outer ring iodine residues and the
fact that only one of them is labeled in a given molecule. Protein
content in the homogenates was determined using the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
Differences between means were obtained by one- or two-
way ANOVA, depending on the experiment, and the Tukey or
Bonferroni post hoc tests, respectively. Calculations were done
using theGraphPadPrism software (http://www.graphpad.com/
prism/). Significance was illustrated graphically by asterisks:
***, P  0.001; **, P  0.01, *, P  0.05.
Results
Selection of genes sensitive to
hypothyroidism in the mouse cerebral
cortex
From previous microarray gene expression
data from the cerebral cortex of P21 control
and hypothyroid mice (27), we selected 43
genes sensitive to thyroid hormone depriva-
tion. Hypothyroidism decreased the expres-
sion of 22of themand increased the expression
of the other 21. We refer to these genes as pos-
itive or negative genes, respectively, indicating
that their expression is likely to be positively or
negatively regulated by thyroid hormone. The
selection of the gene targets among the anno-
tated probes, was performed taking into ac-
count the following two parameters: 1) the ex-
pression levels in the microarrays (the A mean
value above 6; the A mean value is the log2
intensity values over all samples as a measure
of the average expression level) and 2) the re-
sponse to hypothyroidism (the M value of at
least 1.0; M is the log2-fold change between the two con-
ditions). The effects of hypothyroidism on this set of genes
was confirmed by TaqMan PCR arrays on microfluidic
cards using biological replicates of cerebral cortex RNA
from P21 mice (Fig. 1). From the 43-gene set, hypothy-
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FIG. 1. Effect of hypothyroidism on gene expression in the cerebral cortex of P21
wild-type mice as measured using TaqMan arrays. Results are mean  SE of six
animals for each gene. Statistical analysis was by Student’s t test. The set contains
genes already studied (27) and additional genes not previously analyzed (Col6a2,
Cxadr, Flwch2, Fxyd6, Gls2, Gpc3, Hmgcs2, Kcnj10, Pygl, Rassf9, and Shh).
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FIG. 2. Plasma T3 and T4 concentrations in P30 wild-type (WT) and
Dio3KO untreated mice and in T4T3-treated WT and Dio3KO mice
(WT hyper and Dio3KO hyper). Results are mean  SE of eight animals
in each column. Statistical analysis was two-way ANOVA, factors being
genotype and treatment.
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roidism decreased the expression of the 22 genes selected
as positively regulated by thyroid hormone and increased
the expression of the 21 genes selected as negatively reg-
ulated by thyroid hormone. The most common effect of
hypothyroidism was a 50% decreased expression on the
positive genes or a 2-fold increase on the negative genes.
Only a few changes in gene expression were 4-fold or
higher.
Effects of Dio3 inactivation on circulating thyroid
hormone concentrations before and after
treatment with thyroid hormones
The effects of hyperthyroidism on WT and Dio3KO
mice were analyzed by administering high daily doses of
T3 in the drinking water from P21 to P30. Serum T3 and
T4 concentrations in the untreated and treated animals are
shown in Fig. 2. The mean serum concentrations of T3 in
the Dio3KO mice (1.03  5.1 ng/ml) were lower than in
the WT (1.44 0.07 ng/ml), as previously reported (33).
Although the difference was signifi-
cant (P  0.001) using the Student’s
t test, it was not significant using two-
way ANOVA in the four-group com-
parison, which also includes the T3-
treated groups. T3 treatment
increased serum T3 similarly in WT
(10.19  1.07 ng/ml) and Dio3KO
(13.96  2.13) mice. Because T3
treatment was expected to block thy-
roid secretion, theT3-treatedmicewere
also given T4 in physiological amounts
tomaintain normal circulating levels of
T4. T4 concentration in untreated
Dio3KO mice (16.5  1.2 ng/ml) was
significantly reduced compared with
the untreatedWTmice (58.7 1.5 ng/
ml) as found in previous work (26, 33).
In the treated WT and Dio3KO mice,
the T4 concentrations were similar to
the untreated WT (65.0  4.5 and
76.5  7.1 ng/ml, respectively).
Effects of Dio3 inactivation on
cerebrocortical gene expression
before and after treatment with
thyroid hormones
Gene expression levels in the cere-
bral cortex of untreated and treated an-
imals are shown in Figs. 3 (positive
genes) and 4 (negative genes). From the
22 positive genes, 14 showed a differ-
ence in at least one of the experimental
groups using two reference control
RNA, Ppia (cyclophilin) mRNA and 18S RNA (Fig. 3).
The other eight positive genes showed no significant
changes in any of the experimental situations and are not
shown in the figure. D3 inactivation did not affect the
basal expression of most genes except for a small increase
in two of them, Gls2 and Ier5. Thyroid hormone admin-
istration to the WT mice increased the expression of 12
genes, with responses that varied between 1.2-fold (Itga7
and Sema7a) and 2.2-fold (Hr). Two genes (Ppm2c and
Ier5) were unresponsive. D3 inactivation enhanced the T3
response for all genes except for Cbr2. The enhancement
of the T3 effect was notable on genes such as Aldh1a1,
Flywch2, Hr, Itih3, Kcnj10, Paqr6, and Shh, with incre-
ments of 2- to 4-fold the basal expression. Taking into
account all genes, the effects of T3 treatment on the WT
and theDio3KOwere correlated (r 0.689,P 0.0003).
This indicates that, although D3 inactivation did not sig-
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FIG. 3. Effects of D3 inactivation and T4T3 treatment on positive gene expression in the
P30 mouse cerebral cortex. Only the genes showing changes under at least one of the
experimental situations are shown. Results are mean  SE of seven animals for each
condition. Statistical analysis was by two-way ANOVA.
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nificantly influence the basal expression of positive genes,
it enhanced the effect of T3 treatment.
Of the 21 negative genes analyzed, 10 were insensitive
to D3 inactivation and to T3 treatment, and the other 11
showed a significant change in at least one of the experi-
mental situations and are represented in Fig. 4. With the
exception ofMamdc2 andPygl, no effect of hyperthyroid-
ism was observed in the WT mice. However, D3 inacti-
vation significantly reduced the expression of seven genes
(Cirbp,Col6a1,Gpc3, Fxyd6, Pcsk4, Pygl, Syce2). Treat-
ment of Dio3KO mice with T3 resulted in further reduc-
tions in the expression of seven genes (Col6a2, Fxyd6,
Gpc3, Mamdc2, Marcksl1, Pygl, Slc1a3).
We also measured the relative concentrations of Dio2
and Dio3 mRNA as well as D2 and D3 activities in the
same groups of animals (Fig. 5). Dio3 is a positively reg-
ulated gene, and inWTmice T3 treatment increasedDio3
mRNAby 2.7-fold. D3 activity was also increased by 3.6-
fold in the hyperthyroid WT group. Although no D3 ac-
tivitywaspresent in theDio3KOmice,Dio3mRNAcould
be measured in these mice because inactivation of D3 en-
zymatic activity was achieved by mutating the codon cor-
responding to the active site of theD3 protein (34). There-
fore, a minimally modifiedDio3mRNA is still expressed
in Dio3KO animals. At odds with the
response of other positive genes, the ef-
fect of D3 inactivation onDio3mRNA
was stronger (10-fold increase) than the
effect of T3 treatment on the WT mice.
Furthermore, T3 treatment increased
Dio3mRNAby60-fold in theDio3KO
mice.
Dio2 mRNA concentration was
not altered by D3 inactivation, but
was decreased by a factor of 1.7 by T3
treatment in the WT and by 3.3 in the
Dio3KO mice. In contrast, D2 activ-
ity was increased 1.8-fold in the un-
treated Dio3KO mice and was un-
changed in the hyperthyroid groups.
These changes reflect the fact that D2
activity is regulated by T4 concentra-
tions, whereas Dio2 mRNA is sensi-
tive to T3 treatment.
Dio3 expression attenuates T3
action in cultured neuroblastoma
cells
To examine whether cellular changes
in D3 activity indeed modified genomic
responses to T3, we used amouse neuro-
blastomacell line,N2a, stably expressing
the TR1isoform. These cells do not ex-
press the endogenousDio3 gene (not shown). The cellswere
transfected with a Dio3 expression vector. Then T3 was
added at concentrations of 0.1 and 0.5 nM in the presence of
10% fetal calf serum, and the expression of the endogenous
Hr gene was measured by qPCR in RNA isolated from the
whole culture (Fig. 6). In the absence of D3, Hr was very
sensitive to T3 in these cells. T3 increased Hr expression
almost 7-fold at a concentration of 0.1 nM and 65-fold at
0.5 nM.Dio3 expression after transfection interfered with
T3 action and decreased T3 activity by about 50% at the
two concentrations of T3 tested.
A summary of all gene expression data are shown in
Tables 1 and 2. The tables list the gene symbols and names
and the effects of the experimental manipulations de-
scribed. For comparison we also included in the table the
effects ofDio2 inactivation on genes previously reported
(27) and on additional genes (Col6a2, Cxadr, Flwch2,
Fxyd6,Gls2,Gpc3,Hmgcs2,Kcnj10, Pygl,Rassf9, and
Shh) not previously analyzed. In addition, we included
data on cellular expression of genes enriched at least
3-fold in astrocytes or neurons. These data were calcu-
lated from the expression values given by Cahoy et al.
(35) for astrocytes and neurons on P16.Nine genes were
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enriched in astrocytes and 16 in neurons. Given that all
genes were sensitive to thyroid hormone deprivation,
positive and negative genes differed in their responses to
hyperthyroidism and D3 inactivation. More positive
than negative genes were sensitive to hyperthyroidism,
whereas more negative than positive genes were sensi-
tive to D3 inactivation.
A comprehensive analysis of the gene expression
changes in the different experimental situations is illus-
trated in Fig. 7. This figure was constructed taking the
individual data for all the genes shown in the previous
tables. It displays the reciprocal changes of expression of
positive and negative genes. In contrast to the negative
genes that show altered expression in all the experimental
situations, the positive genes are remarkably stable in sit-
uations of D2 or D3 deficiency and show altered expres-
sion only in hypo- or hyperthyroidism.
Discussion
The important role of D3 in the control of tissue T3 con-
centration has been recently demonstrated using geneti-
cally modified mice (26, 33). To gain further insight into
the role of D3 in modulating T3 action in the brain, we
used WT andDio3KO mice to investigate the expression
of a relatively large set of thyroid hormone-sensitive genes
identified by microarray analysis of the cerebral cortex of
P21 mice (27). After confirming the sensitivity of these
genes to thyroid hormone deprivation, we compared the
effects of D3 deficiency with those of induced hyperthy-
roidism andD2 deficiency. The age to perform the present
investigationwas chosen as the same atwhich the sensitive
genes were identified. This report contains the largest set
of brain genes analyzed so far in terms of their dependency
to thyroid hormones. A limitation of the study is that the
brain ofDio3KOmicemanifests abnormal exposure toT3
since early development, and this is maintained through-
out life (33). As a result, it might be possible that unin-
tended, permanent changes at the molecular level are in-
fluencing the signaling pathways that determine the
response toT3 later in life.Although this kindof drawback
is generally shared by studies involving germ line gene
mutations, it should be kept in mind when extrapolating
experimental observations from these mouse models to
the normal physiology.
D3 deficiency did not have a marked impact in thyroid
hormone-dependent gene expressionbecause it altered the
expression of only two positive genes and seven negative
genes. This is somewhat surprising, given that D3 expres-
sion in the cerebral cortex at this age is comparable with
that at an early postnatal age, when significant changes in
the expression of the T3-sensitive genes, Hr and Nrgn,
have been reported in the Dio3KO mice (26). This does
not necessarily mean that D3 is not an important deter-
minant of basal brain T3 action at this age. Although D3
deficiency generally tends to increase brain T3 availability
at all developmental stages, we have to take into consid-
eration the suppression exerted on the thyroid axis and on
serum levels of T3 and T4. This suppression is most dra-
matic during the third week of life (26) and may be re-
sponsible for the reduced brain expression of the T3-sen-
sitive genes, Nrgn and Hr, on P17 and P21 (33). Hr
expression thenbecomes normalized onP30as in the pres-
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ent study. Thus, at this age, theDio3KObrainmay still be
significantly influenced by the serum hypothyroid status,
which would be consistent with previous results (26).
However, theDio3mRNA concentration in the untreated
Dio3KOmice was elevated up to 10-fold, indicating that
these animalsmay actually have an increased T3 availabil-
ity in the brain despite the lack of effect on most positive
genes. A large fraction of brain T3 is generated locally in
the brain (36), and although Dio2 mRNA was not in-
creased in theDio3KOmice, D2 activity in the cortexwas
increased, in agreement with previous observations (26).
Therefore, the concerted action of D2 and D3 activities
appears more important for brain homeostasis than the
circulating T3 concentrations. Presumably a more robust
effect of D3 deficiency on cortical gene expression at this
age might be achieved in a tissue specific model of D3
deficiency that leaves the thyroid axis unaffected.
Further evidence of an important role for D3 derives
from the results in the animals treatedwithT3. InDio3KO
mice, T3 treatment led to responses in gene expression that
were larger than those in WT mice. It seems unlikely that
this was due to differences in the basal concentrations of
T3 at the start of treatment,which, if any,wouldhave been
overridden by the large dose of T3 administered. The pro-
tection afforded by D3 may be largely secondary to in-
creased expression of the Dio3 gene, which is strongly
up-regulated by T3 (24). In this regard, we observed an
increased D3 activity in the T3-treatedWTmice as well as
dramatic increases inDio3mRNA expression in WT and
Dio3KO animals after T3 treatment, demonstrating the
great sensitivity of the Dio3 gene to T3. In addition to a
direct transcriptional effect of T3, other factors such as
increased stability of the mutated mRNA may have con-
tributed to the large induction observed in the untreated
and treated Dio3KO mice compared with the respective
WT animals. Interestingly, T3 induces theDio3 gene spe-
cifically through the TR1 isoform (37). Therefore, it is
possible that the protecting effect afforded by the in-
creased expression of Dio3 may depend on the relative
expression of TR1 in specific cell types.
A direct role of D3 in the regulation of the genomic
responses to T3 was demonstrated in neuroblastoma cells
TABLE 1. Summary of the effects of hypo- and hyperthyroidism and D3 or D2 deficiencies on the expression of
cerebral cortex genes
Positive genes
Fold enrichment
in cell type Fold change
Gene symbol Gene name Astro Neuron Hypo Hyper Dio3 KO Dio3 KOT3 Dio2 KO
Abcd2 ATP-binding cassete, subfamily D,
member 2
18 1.9 1.3 nc 1.5 nc
Afap1l1 Actin filament-associated protein 1 2.4 nc nc nc nc
Aldh1a1 Aldehyde dehydrogenase family 1,
subfamily A1
13 6.3 1.6 nc 2.0 nc
Cbr2 Carbonyl reductase 2 4.8 1.8 nc 1.5 nc
Cntn2 Contactin 2 (TAG-1) 5 1.9 nc nc nc nc
Flwch2 FLYWCH family member 2 3 1.7 1.5 nc 2.8 nc
Gls2 Glutaminase 2 14 2.4 1.3 1.2 1.5 nc
Hr Hairless 6.3 2.2 nc 4.7 nc
Luzp1 Leucine zipper protein 1 1.7 nc nc nc nc
Nefh Neurofilament, heavy polypeptide 37 1.9 nc nc nc nc
Nefm Neurofilament, medium polypeptide 83 2.4 nc nc nc nc
Rbm3 RNA binding motif protein 3 2.4 nc nc nc 2.0
Ier5 Immediate early response 5 3.2 nc 1.2 1.6 nc
Itga7 Integrin 7 3 2.1 1.2 nc 1.6 nc
Itih3 Inter- trypsin inhibitor, heavy chain 3 2.1 2.0 nc 3.5 nc
Kcnj10 Potassium inwardly rectifying channel,
subfamily J, member 10
3 4.8 1.5 nc 2.6 1.6
Paqr6 Progestin and adipoQ receptor family
member VI
6 2.1 1.5 nc 2.1 nc
Ppm2c Pyruvate dehyrogenase phosphatase
catalytic subunit 1
4 2.1 nc nc 1.5 nc
Sema7a Semaphorin 7A 5 2.7 1.2 nc 1.4 nc
Shh Sonic hedgehog 5 2.1 1.5 nc 3.5 1.6
Stac2 SH3 and cysteine rich domain 2 3.2 nc nc nc nc
Stard4 StAR-related lipid transfer (START) domain
containing 4
2.1 nc nc nc nc
This is a summary of changes in expression of positive genes as measured by qPCR. Genes of enriched expression more than 3-fold in astrocytes or
neurons are indicated. Values for enrichment were obtained from the published database by Cahoy et al. (35). nc, No change.
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after transfection with a Dio3 expression vector. The Hr
response to T3 was attenuated by about 50% in compar-
ison with cells not expressingDio3. TheHr response was
measured in RNA from all cells in the culture, of which
18% were transfected. Therefore, it is likely that Dio3
expression in a fractionof the cells in culturewas sufficient
to reduce the free T3 concentration in
the medium.
Concerning the negative genes, from
the original set of 21 genes, seven had a
lower expression in the Dio3KO than
in the WT. Treatment with excess T3
had a modest effect on the WT, and in
some cases the effect of Dio3 inactiva-
tion was similar to the effect of T3 ad-
ministration. The results indicate that
some negative genes are very sensitive
to local increments of T3 concentration
that might have taken place as a result
ofD3 inactivation.The comparative re-
sponse of these genes to hyperthyroid-
ismand toD3 inactivationmay indicate
that the local T3 concentrations at-
tained in D3 deficiency are higher than
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FIG. 7. Effects of the different manipulations affecting the supply and metabolism of thyroid
hormones on negatively and positively regulated genes. To construct this figure, we used all the
single qPCR data from the genes shown in Figs. 3 and 4,to calculate the fold change, relative to
the WT values, and plotted the Log2FC (fold change) to make the results quantitatively
comparable. The data were represented in a box-and-whiskers (5–95%) plot. Statistical
significance between each group and the WT was calculated by one-way ANOVA. For the positive
genes, F5, 537 272, P 0.0001. For the negative genes, F5, 400 145, P 0.0001.
TABLE 2. Summary of the effects of hypo- and hyperthyroidism and D3 or D2 deficiencies on the expression of
cerebral cortex genes
Negative genes
Fold enrichment
in cell type Fold change
Gene symbol Gene name Astro Neuron Hypo Hyper Dio3 KO Dio3 KOT3 Dio2 KO
Agbl3 ATP/GTP binding protein-like 3 1.6 nc nc nc 2.8
Cirbp Cold inducible RNA binding protein 2.2 nc 1.3 1.3 2.3
Col6a1 Collagen, type VI, 1 32 2.4 nc 1.3 1.3 1.9
Col6a2 Collagen, type VI, 2 2.4 nc nc 1.3 2.4
Cxadr Coxsackie virus and adenovirus receptor
(CAR)
40 4.5 nc nc nc 2.3
Dgkg Diacylglycerol kinase,  7 4.0 nc nc nc nc
Fxyd6 FXYD domain-containing ion transport
regulator 6
6 2.4 nc 1.3 1.9 nc
Gpc3 Glypican 3 11 2.4 nc 1.3 1.7 nc
Hapln1 Hyaluronan and proteoglycan link
protein 1
8 2.0 nc nc nc nc
Hmgcs2 3-hydroxy-3-methylglutaryl-coenzyme A
synthase 2
5 4.0 nc nc nc 2.0
Icosl Icos ligand 2.2 nc nc nc nc
Mamdc2 MAM domain-containing proteoglycan 4 2.9 1.3 nc 2.0 1.8
Marcksl1 MARCKS-like 1 6 1.5 nc nc 1.5 3.6
Odf4 Outer dense fiber of sperm tails 4 2.7 nc nc nc 2.2
Pcsk4 Proprotein convertase subtilisin/kexin
type 4
2.0 nc 1.4 1.4 nc
Pygl Glycogen phosphorylase 2.0 1.2 1.2 1.5 nc
Rassf9 Ras association (RalGDS/AF-6) domain
family (N terminal) member 9
2.9 nc nc nc nc
Slc1a3 Glial high-affinity glutamate transporter 37 1.8 nc nc 1.3 nc
Slc16a1 Monocarboxylic acid transporter 1 3 2.2 nc nc nc 2.6
Sult1a1 Sulfotransferase family 1A, phenol-
preferring, member 1
7 2.0 nc nc nc 1.9
Syce2 Synaptonemal complex central element
protein 2
2.2 nc 1.5 1.9 nc
This is a summary of changes in expression of negative genes as measured by qPCR. Genes of enriched expression more than 3-fold in astrocytes
or neurons are indicated. Values for enrichment were obtained from the published database by Cahoy et al. (35). nc, No change.
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those resulting from treatmentwith an excess of T3.How-
ever, this conclusion is not supported by the response of
the positive genes.We do not have an explanation for this
paradox, but it may reflect subtle spatial differences in T3
concentrations affecting only certain subsets of cells.
Another observation worth to explore further is that
noneof the10geneswith enrichedexpression inastrocytes
were sensitive to D3 inactivation. In contrast, from the 17
genes, includingDio3, not enriched in astrocytes, 10were
sensitive to D3 inactivation. Because D3 is a neuronal en-
zyme, this could be explained by a preferential accumu-
lation of T3 in neurons. Because Dio3KO mice manifest
increased brain D2 activity due to reduced T4 availability
(26), it would be expected that astrocytes provide an in-
creased supply of T3 to neurons. However, the number of
genes analyzed in this work is too limited to reach defin-
itive conclusions, and examination of the global expres-
sion of neuronal and astrocytic genes in the context of D3
inactivation would be needed.
Although all genes analyzed were highly sensitive to
hypothyroidism, it is interesting to note that eight positive
genes and 10 negative genes were insensitive to adminis-
tration of high doses of T3, either to WT or to Dio3KO
mice. This indicates a failure of thyroid hormone to in-
crease their expression above the level associated with eu-
thyroid status. This may be due to the high basal occu-
pancyof cortex thyroidhormone receptors,which in adult
rats at steady state was calculated to be as high as 90%
(36). Individual gene differences in the T3 response may
reflect cellular heterogeneity in thyroid hormone receptor
occupancy, which should be expected because D2 activity
accounts for a large fraction of the total occupancy. An-
other explanation is that some genes are regulated only in
the transition from hypothyroidism to euthyroidism. In
hypothyroidism the activity of unliganded receptors (38)
may contribute to repression of the positive genes and the
induction of the negative genes. Similar differences in the
response to hypothyroidism and to excess T3were already
noted for different gene clusters in the liver (39).
Previous data indicated that the negative genes are
more sensitive to the absence ofD2 than the positive genes
(27). As shown in this work, negative genes are also more
sensitive to the absence ofD3.Thismay reflect a difference
between positive and negative genes in the kinetics of their
response to changes in T3 concentrations. Figure 7 shows
the reciprocal changes in the expression of the genes that
were sensitive to each of themanipulations. However, it is
not possible to correlate these changes with T3 concen-
tration in the whole tissue. For example, T3 concentra-
tions in the cerebral cortex of Dio2KO are similar to hy-
pothyroid WT mice (40). But from the expression of the
positive genes, it could be predicted that there are no
changes of T3 concentration, whereas from the negative
genes, one could reach a different conclusion.
In summary, our results demonstrate a role for D3 in
the regulation of T3-dependent gene expression in the ce-
rebral cortex. They also suggest that, when thyroid hor-
mone brain status is close to physiological conditions,
genes that are negatively regulated by T3 in the cerebral
cortex are the most sensitive to subtle changes in local T3.
In this scenario, the coordinated expression of D2 and D3
appears to be necessary for maintaining the expression of
these geneswithin narrow limits. These results underscore
the fine-tuning of the factors influencing local T3 avail-
ability in the central nervous system.
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